- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05533346
Long-term Effects of WISE Program Improving Frailty Status and Quality of Life for Adolescents With CHD
March 20, 2024 updated by: National Yang Ming University
Long-term Effects of WISE Program Improving Frailty Status and Quality of Life for Adolescents With Congenital Heart Disease
Most children with congenital heart disease (CHD) are expected to survive until adulthood.
In addition to physical limitations, the growing adolescents with CHD are also challenged at the psychosocial domains.
Previous studies have investigated the frailty of elderly, but the research on the intervention to the frailty of adolescents with CHD has been limited.
The aims of this study will apply the Walking Instruction based on Self-Efficacy (WISE) program to examine the long-term effects of improving frailty state and quality of life for adolescents with CHD.
Study Overview
Status
Withdrawn
Conditions
Detailed Description
This proposal will conduct a three-year series of studies.
In the first year, a cross-sectional survey will be used to evaluate the applicability of the Fried frailty index to adolescents with CHD, and to examine the correlation between frailty index and quality of life in adolescent patients.
In the second year, investigators will conduct individual in-depth interviews with selected pre-frailty/frailty adolescent participants and their main caregivers to gain insights into their views, connotations and support needs for frailty, which will serve as the basis for the design of the next interventional study.
In the third year, the WISE program will be developed to provide 12-week walking self-efficacy improvement education strategies and exercise bracelets with heart rate monitoring.
The recruited pre-frailty/frailty adolescent participants will be randomly assigned to experimental and control groups respectively in the pretest-posttest control group design.
The changes in frailty state and quality of life for the two groups will be evaluated at 6, 12 and 24 weeks.
The results of this study can provide frailty evaluation indicators for adolescents with CHD, timely detect the pre-frailty stage, and provide an important reference for the prevention of frailty intervention for adolescents with CHD as early as possible.
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taipei, Taiwan, 11221
- National Yang Ming Chiao Tung University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
8 years to 14 years (Child, Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Aged between 12-18 years old.
- Congenital heart disease diagnosed by a doctor before the age of 2.
- The American New York Heart Association (NYHA) classifies the cardiac function as I-III grades.
- Adolescents and their parents or guardians can communicate in Mandarin and Taiwanese and have normal cognitive abilities.
- Those who are willing to cooperate with the research and complete the consent form.
Exclusion Criteria:
- Received a heart transplant within one year.
- Have undergone open-heart surgery within six months.
- The New York Heart Association (NYHA) classifies the cardiac function as class IV.
- Combined with other congenital diseases.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Experimental - with WISE
The experimental group will provide walking health education leaflets and exercise measurement wristbands for exercise monitoring, and will be given the intervention of the WISE program: three times a week, each time walking for at least 30 minutes, with a pace between 100-130 steps/ minutes, and then increase the number or time weekly according to personal ability.
|
Will be provided with walking health education leaflets and exercise measurement wristbands for exercise monitoring.
Only the experimental group will be additionally given the interventional treatment of the WISE program: walk three times a week for at least 30 minutes each time, with a pace between 100-130 steps/min, and then increase the number or time weekly according to your personal ability, and remind you if the monitoring heart rate is higher than 170 times/min or the blood oxygen concentration is lower than 95%, and if the body feels any discomfort, it is necessary to stop taking a rest, and an educational strategy for improving self-efficacy of walking for 12 weeks is also provided.
|
|
Active Comparator: Control - without WISE
The procedure of the control group will be the same as that of the experimental group, providing walking and health education leaflets and exercise measurement wristbands for exercise monitoring, but no intervention in the WISE program.
|
The procedure of the control group was the same as that of the experimental group, both of which will be provided with walking health education leaflets and exercise measurement wristbands for exercise monitoring.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frailty Status
Time Frame: change from baseline to post-intervention at 6-week follow-up
|
The frailty phenotype and measurement method proposed by Fried et al. (2001) were modified to be suitable for use by adolescents.
The five aspects of the assessment included decreased muscle strength, slow walking, thin body composition, self-reported fatigue and Decreased physical activity.
|
change from baseline to post-intervention at 6-week follow-up
|
|
Frailty Status
Time Frame: change from baseline to post-intervention at 12-week follow-up
|
The frailty phenotype and measurement method proposed by Fried et al. (2001) were modified to be suitable for use by adolescents.
The five aspects of the assessment included decreased muscle strength, slow walking, thin body composition, self-reported fatigue and Decreased physical activity.
|
change from baseline to post-intervention at 12-week follow-up
|
|
Frailty Status
Time Frame: change from baseline to post-intervention at 24-week follow-up
|
The frailty phenotype and measurement method proposed by Fried et al. (2001) were modified to be suitable for use by adolescents.
The five aspects of the assessment included decreased muscle strength, slow walking, thin body composition, self-reported fatigue and Decreased physical activity.
|
change from baseline to post-intervention at 24-week follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of life for adolescents with congenital heart disease
Time Frame: change from baseline to post-intervention at 6-week follow-up
|
Quality of life scale for adolescents with congenital heart disease (PedsQLTM 3.0 Cardiac Module) will be used to measure participant's quality of life.
This scale is divided into five aspects for measurement, including disease status, physical appearance, treatment anxiety, cognitive status and communication ability assessment.
Those who take heart disease medicines must answer a total of 27 questions; those who do not take heart disease medicines have 22 questions, and each question has five options. 1 point for "yes", 2 points for "sometimes", 3 points for "often", and 4 points for "almost always".
The lower the score, the better the quality of life.
|
change from baseline to post-intervention at 6-week follow-up
|
|
Quality of life for adolescents with congenital heart disease
Time Frame: change from baseline to post-intervention at 12-week follow-up
|
Quality of life scale for adolescents with congenital heart disease (PedsQLTM 3.0 Cardiac Module) will be used to measure participant's quality of life.
This scale is divided into five aspects for measurement, including disease status, physical appearance, treatment anxiety, cognitive status and communication ability assessment.
Those who take heart disease medicines must answer a total of 27 questions; those who do not take heart disease medicines have 22 questions, and each question has five options. 1 point for "yes", 2 points for "sometimes", 3 points for "often", and 4 points for "almost always".
The lower the score, the better the quality of life.
|
change from baseline to post-intervention at 12-week follow-up
|
|
Quality of life for adolescents with congenital heart disease
Time Frame: change from baseline to post-intervention at 24 week follow-up
|
Quality of life scale for adolescents with congenital heart disease (PedsQLTM 3.0 Cardiac Module) will be used to measure participant's quality of life.
This scale is divided into five aspects for measurement, including disease status, physical appearance, treatment anxiety, cognitive status and communication ability assessment.
Those who take heart disease medicines must answer a total of 27 questions; those who do not take heart disease medicines have 22 questions, and each question has five options. 1 point for "yes", 2 points for "sometimes", 3 points for "often", and 4 points for "almost always".
The lower the score, the better the quality of life.
|
change from baseline to post-intervention at 24 week follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
July 1, 2023
Primary Completion (Estimated)
December 30, 2024
Study Completion (Estimated)
December 30, 2025
Study Registration Dates
First Submitted
September 6, 2022
First Submitted That Met QC Criteria
September 6, 2022
First Posted (Actual)
September 9, 2022
Study Record Updates
Last Update Posted (Actual)
March 22, 2024
Last Update Submitted That Met QC Criteria
March 20, 2024
Last Verified
September 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202112099RINA-202200361B0
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Frailty
-
University of PennsylvaniaCompleted
-
McMaster UniversityRecruitingFrailty | Frailty Syndrome | Frail Older Adults | Frailty in AgingCanada
-
University of IcelandLandspitali University HospitalRecruitingFrailty Syndrome | Elective Surgery | Frailty in Adult SurgeryIceland
-
Universidad Francisco de VitoriaNot yet recruitingFrailty Syndrome | Respiratory Muscle Weakness | Age-Related Frailty | Geriatric Health
-
Universidad Francisco de VitoriaActive, not recruitingFrailty Syndrome | Respiratory Muscle Weakness | Age-Related Frailty | Geriatric HealthSpain
-
Ji Yan Biomedical Co., Ltd.YC Biotech Co., Ltd.Not yet recruiting
-
Universidad Francisco de VitoriaNot yet recruitingFrailty Syndrome | Respiratory Muscle Weakness | Age-Related Frailty | Geriatric Health
-
University of NottinghamRecruitingFrailty | Diet | Systemic Inflammatory Response | Dietary Fiber | Frailty at Older Adults | Pre-FrailtyUnited Kingdom
-
National Taipei University of Nursing and Health...Not yet recruiting
-
IRCCS Centro San Giovanni di Dio FatebenefratelliCompleted
Clinical Trials on with WISE (Walking Instruction based on Self-Efficacy)
-
University of BernSuzanne und Hans Biäsch FoundationCompletedWork Related Stress | Behavior, Health | Behavior, MaternalNepal
-
Tuğba SarıCompleted
-
Akdeniz UniversityUnknownPeritoneal Dialysis | Self Efficacy | Perceived Social Support | Self-CareTurkey
-
Psychiatric Research Unit, Region Zealand, DenmarkUniversity of CopenhagenCompleted
-
University of California, Los AngelesVirginia Commonwealth University; United States Naval Medical Center, San Diego and other collaboratorsRecruiting
-
Akdeniz UniversityCompletedStroke, Ischemic | Self EfficacyTurkey
-
H. Lee Moffitt Cancer Center and Research InstituteAmerican Cancer Society, Inc.Completed
-
University of IdahoNational Institute of General Medical Sciences (NIGMS); Oregon State University and other collaboratorsRecruitingPostpartum Depression | Preterm LaborUnited States
-
Memorial Sloan Kettering Cancer CenterBoehringer Ingelheim; National Comprehensive Cancer NetworkCompletedHead and Neck Cancer | Squamous Cell CancerUnited States